Dienogest (Visabelle®) is a selective progestin, combining the pharmacological properties of 19-norprogestins with progesterone derivatives, and has a pronounced effect on endometrial tissue.

An EU marketing authorisation application for the use of dienogest to treat endometriosis was granted by The Netherlands in December 2009.

Thie review evaluates the data available supporting the use of dienogest for the treatment of endometriosis.